Prospects of targeting the gastrin releasing peptide receptor and somatostatin receptor 2 for nuclear imaging and therapy in metastatic breast cancer
Files
Publication date
2017-01-20
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Background The gastrin releasing peptide receptor (GRPR) and the somatostatin receptor 2 (SSTR2) are overexpressed on primary breast cancer (BC), making them ideal candidates for receptor- mediated nuclear imaging and therapy. The aim of this study was to determine whether these receptors are also suitable targets for metastatic BC. Methods mRNA expression of human BC samples were studied by in vitro autoradiography and associated with radioligand binding. Next, GRPR and SSTR2 mRNA levels of 60 paired primary BCs and metastases from different sites were measured by quantitative reverse transcriptase polymerase chain reaction. Receptor mRNA expression levels were associated with clinico-pathological factors and expression levels of primary tumors and corresponding metastases were compared. Results Binding of GRPR and SSTR radioligands to tumor tissue correlated significantly with receptor mRNA expression. High GRPR and SSTR2 mRNA levels were associated with estrogen receptor (ESR1)-positive tumors (p
Keywords
Gene expression, Lymph nodes, Autoradiography, Metastatic tumors, metastasis, Cancer treatment, Messenger RNA, breast cancer, General Medicine, General Biochemistry,Genetics and Molecular Biology, General Agricultural and Biological Sciences, Journal Article
Citation
Dalm, S U, Schrijver, W A M E, Sieuwerts, A M, Look, M P, Ziel-Van Der Made, A C J, De Weerd, V, Martens, J W, Van Diest, P J, De Jong, M & Van Deurzen, C H M 2017, 'Prospects of targeting the gastrin releasing peptide receptor and somatostatin receptor 2 for nuclear imaging and therapy in metastatic breast cancer', PLoS ONE [E], vol. 12, no. 1, e0170536. https://doi.org/10.1371/journal.pone.0170536